Please login to the form below
New US head for Daiichi Sankyo
Glenn Gormley replaces John Gargiulo who steps down as president and CEO
Daiichi Sankyo has announced a shake-up of its senior leadership team in the US.
John Gargiulo well step down as president and CEO of the group's US subsidiary Daiichi Sankyo Inc to be replaced by Dr Glenn Gormley, who takes on the role of president and chairman.
Dr Gormley (pictured right) will also continue in his existing roles as president, Daiichi Sankyo pharma development; global head of R&D; and senior executive officer.
In addition to the announcement that Gargiulo is to step down as president and CEO, he will also leave his role as head of Daiichi's commercial division. He is succeeded there by Greg Barrett, who now holds the title of acting president, Daiichi Sankyo administrative and commercial operations.
The move is a step up for Barrett, who most recently held the position of VP, marketing and managed markets in the US.
No reason was given for the departure of Gargiulo who has been with the company in the US since 1996.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Takeda’s dengue vaccine receives MHRA approval for those aged four years and older
- Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis
- Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients
- NHS urges people yet to receive their COVID-19 booster to come forward
- Biosimilars and beyond: innovating for improved patient outcomes
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Why female mentorship is so powerful in pharma
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Digital technology: a significant change in healthcare innovation
- Assessing the value of interim analyses in clinical trials
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- Biosimilars and beyond: innovating for improved patient outcomes
- How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
